The results show that there is a considerable difference in YTHDC2 expression in the vast majority of malignant tumours, and moreover, YTHDC2 is tumour‐suppressive in most cancers and is oncogenic in a few tumours, respectively. Here, YTHDC2 is linked to neoplasm.